Guggenheim Capital LLC Lowers Stake in Humana Inc. $HUM

Guggenheim Capital LLC cut its position in Humana Inc. (NYSE:HUM) by 30.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,560 shares of the insurance provider’s stock after selling 3,795 shares during the period. Guggenheim Capital LLC’s holdings in Humana were worth $2,093,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Humana by 16.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,136,538 shares of the insurance provider’s stock valued at $300,728,000 after acquiring an additional 158,528 shares during the last quarter. Focus Partners Wealth lifted its position in Humana by 104.2% during the first quarter. Focus Partners Wealth now owns 6,429 shares of the insurance provider’s stock valued at $1,701,000 after purchasing an additional 3,281 shares during the last quarter. Swedbank AB grew its stake in shares of Humana by 5.3% in the 2nd quarter. Swedbank AB now owns 100,397 shares of the insurance provider’s stock worth $24,545,000 after buying an additional 5,032 shares in the last quarter. Circle Wealth Management LLC bought a new stake in shares of Humana in the 1st quarter worth about $425,000. Finally, Kera Capital Partners Inc. purchased a new stake in shares of Humana during the 2nd quarter valued at about $253,000. 92.38% of the stock is currently owned by institutional investors.

Humana Price Performance

HUM opened at $250.04 on Wednesday. The company has a quick ratio of 2.02, a current ratio of 2.02 and a debt-to-equity ratio of 0.68. The business has a fifty day moving average of $262.35 and a 200 day moving average of $257.72. Humana Inc. has a 52-week low of $206.87 and a 52-week high of $315.35. The stock has a market cap of $30.07 billion, a P/E ratio of 23.43, a PEG ratio of 1.50 and a beta of 0.46.

Humana (NYSE:HUM) last released its earnings results on Wednesday, November 5th. The insurance provider reported $3.24 earnings per share for the quarter, topping the consensus estimate of $2.95 by $0.29. The business had revenue of $32.65 billion during the quarter, compared to the consensus estimate of $31.99 billion. Humana had a return on equity of 12.86% and a net margin of 1.02%.The business’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period last year, the company earned $4.16 earnings per share. As a group, sell-side analysts anticipate that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Friday, December 26th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.4%. The ex-dividend date is Friday, December 26th. Humana’s dividend payout ratio is currently 33.18%.

Analyst Upgrades and Downgrades

Several research analysts recently commented on HUM shares. Wolfe Research dropped their price target on Humana from $313.00 to $300.00 and set an “outperform” rating for the company in a research report on Thursday, November 20th. Royal Bank Of Canada boosted their target price on Humana from $283.00 to $322.00 and gave the company an “outperform” rating in a research report on Thursday, August 21st. Guggenheim restated a “buy” rating on shares of Humana in a report on Friday, October 3rd. Jefferies Financial Group raised shares of Humana from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $253.00 to $313.00 in a research note on Friday. Finally, Sanford C. Bernstein boosted their price objective on shares of Humana from $269.00 to $341.00 and gave the company an “outperform” rating in a research report on Friday, September 5th. Nine equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $296.84.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.